FCM
BMY icon

Fieldview Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Fieldview Capital Management’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-29,673
Closed -$1.6M – 503
2025
Q4 		$1.6M Sell
29,673
-29,022
-49% -$1.4M 0.27% 122
2025
Q3 		$2.65M Buy
58,695
+46,347
+375% +$2.16M 0.43% 88
2025
Q2 		$572K Sell
12,348
-58,381
-83% -$2.87M 0.09% 235
2025
Q1 		$4.31M Buy
70,729
+47,284
+202% +$2.76M 0.61% 41
2024
Q4 		$1.33M Buy
+23,445
New +$1.31M 0.2% 152

Other funds holding BMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fieldview Capital Management's BMY Position: Q1 2026 in Review

Fieldview Capital Management sold out of Bristol-Myers Squibb (BMY) in Q1 2026, closing a stake of 29,673 shares — an estimated $1.6M sold.

Fieldview Capital Management first reported a position in BMY in Q4 2024 and held it in 5 quarters. The position peaked at $4.31M in Q1 2025. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Fieldview Capital Management reported no remaining Bristol-Myers Squibb position as of Q1 2026 after selling out during the quarter.
  • Fieldview Capital Management sold 29,673 Bristol-Myers Squibb shares in Q1 2026, an estimated $1.6M.
  • Fieldview Capital Management first reported a position in Bristol-Myers Squibb in Q4 2024 and held it in 5 quarters.
  • Fieldview Capital Management's Bristol-Myers Squibb position peaked at $4.31M in Q1 2025.
  • 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Fieldview Capital Management's 13F filing for Q1 2026, filed 14 May 2026.